Comparing Ways of Taking HIV Medicine in People With AIDS-Related Lymphoma
Compares oral and long-acting injected HIV drugs in adults with AIDS-related lymphoma.
Plain-language title generated from the registry record
Registry title: Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with HIV infection and lymphoma linked to AIDS who are having lymphoma treatment. It compares different HIV medicine plans.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- AIDS-related lymphoma confirmed by tissue examination, with lymphoma treatment under way
- Earlier treatment
- Must be receiving anti-lymphoma treatment now
- Biomarker or test result
- Confirmed HIV infection
Main reasons for not taking part
- Expected survival less than 6 months
- Severe other cancer or uncontrolled other illness
- Refusing HIV treatment or lymphoma treatment
- Reasons the study drugs cannot be used
- Unable to complete the scheduled follow-up visits
Read by machine on 12 November 2026.
Where in China
- Shanghai Public Health Clinical CenterShanghai, ChinaContact: Zhenyan WangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Public Health Clinical Center
- Trial code
- NCT07727642
- Record updated
- 27 July 2026
- Original description
The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strategies in adults with AIDS-related lymphoma (ARL) receiving anti-lymphoma treatment. The main questions it aims to answer are:Read full original descriptionShow less
Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma During Anti-Lymphoma Treatment: A Multicenter Prospective Non-Randomized Controlled Study
The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strategies in adults with AIDS-related lymphoma (ARL) receiving anti-lymphoma treatment. The main questions it aims to answer are:
Does long-acting injectable ART, including albuvirtide (ABT) or long-acting cabotegravir/rilpivirine (CAB/RPV), improve virological suppression compared with oral ART during anti-lymphoma treatment? Do different ART strategies differ in immune recovery, virological failure, low-level viremia, and safety in patients with ARL?
Researchers will compare three treatment strategies-oral ART alone, oral ART plus long-acting albuvirtide (ABT), and long-acting cabotegravir/rilpivirine (CAB/RPV)-to determine whether long-acting injectable ART provides better virological control and comparable safety during lymphoma treatment.
Participants will:
Receive one of three ART strategies according to their clinical condition and treatment preference while receiving standard anti-lymphoma therapy.
Attend scheduled study visits at baseline and Weeks 4, 8, 12, 24, 36, and 48. Undergo plasma HIV-1 RNA testing, CD4+ T-cell count measurement, laboratory assessments, and safety evaluations throughout the 48-week follow-up period.
Be monitored for virological suppression, immune recovery, adverse events, and lymphoma-related clinical outcomes.
Inclusion: Age ≥18 years. Confirmed HIV infection. Histologically confirmed AIDS-related lymphoma. Receiving anti-lymphoma treatment. Able and willing to provide written informed consent.
Exclusion: Expected survival less than 6 months. Severe concomitant malignancy or uncontrolled comorbidity. Refusal to receive antiretroviral therapy or lymphoma treatment. Contraindications to study medications. Inability to complete scheduled follow-up. Any condition considered unsuitable by the investigator.